Bank Julius Baer & Co
BCLI

Bank Julius Baer & Co’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Bank Julius Baer & Co’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-278
Closed -$17K – 607
2021
Q4 		$17K Hold
278
– – ﹤0.01% 752
2021
Q3 		$14K Sell
278
-3
-1% -$158 ﹤0.01% 765
2021
Q2 		$16K Buy
281
+3
+1% +$160 ﹤0.01% 766
2021
Q1 		$16K Sell
278
-2
-0.7% -$151 ﹤0.01% 760
2020
Q4 		$19K Sell
280
-131
-32% -$17.8K ﹤0.01% 749
2020
Q3 		$104K Buy
411
+1
+0.2% +$205 ﹤0.01% 563
2020
Q2 		$69K Buy
410
+134
+49% +$14.4K ﹤0.01% 543
2020
Q1 		$19K Buy
+276
New +$21.5K ﹤0.01% 583

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return

Bank Julius Baer & Co's BCLI Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2022, closing a stake of 278 shares — an estimated $17K sold.

Bank Julius Baer & Co first reported a position in BCLI in Q1 2020 and held it in 8 quarters. The position peaked at $104K in Q3 2020. 39 funds tracked by Wall St. Rank hold BCLI as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 278 BRAINSTORM CELL THERAPUTC shares in Q1 2022, an estimated $17K.
  • Bank Julius Baer & Co first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 8 quarters.
  • Bank Julius Baer & Co's BRAINSTORM CELL THERAPUTC position peaked at $104K in Q3 2020.
  • 39 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.